EMA/868576/2018

European Medicines Agency decision

P/0403/2018

of 19 December 2018

on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate), (SIRTURO), (EMEA-000912-PIP01-10-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0403/2018

of 19 December 2018

on the acceptance of a modification of an agreed paediatric investigation plan for bedaquiline (fumarate), (SIRTURO), (EMEA-000912-PIP01-10-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/55/2011 issued on 4 March 2011, the decision P/0105/2013 issued on 30 April 2013, the decision P/0065/2015 issued on 1 April 2015 and the decision P/0371/2016 issued on 4 January 2017,

Having regard to the application submitted by Janssen-Cilag International NV on 9 August 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 16 November 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for bedaquiline (fumarate), (SIRTURO), tablet, granules, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 - Beerse, Belgium.

EMA/PDCO/565712/2018 Corr
London, 16 November 2018

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000912-PIP01-10-M04

Scope of the application

Active substance(s):

Bedaquiline (fumarate)

Invented name:

SIRTURO

Condition(s):

Treatment of multi-drug resistant tuberculosis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Tablet

Granules

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Janssen-Cilag International NV

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Janssen-Cilag International NV submitted to the European Medicines Agency on 9 August 2018 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/55/2011 issued on 4 March 2011, the decision P/0105/2013 issued on 30 April 2013, the decision P/0065/2015 issued on 1 April 2015 and the decision P/0371/2016 issued on 4 January 2017.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 18 September 2018.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric Investigation Plan

2.1. Condition

Treatment of multi-drug resistant tuberculosis

2.1.1. Indication(s) targeted by the PIP

Treatment of multi-drug resistant tuberculosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Tablet

Granules

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	**Study 1** Development of an age appropriate formulation
Non-clinical studies	1	**Study 2** Juvenile toxicity study in rats
Clinical studies	2	**Study 3** Open-label, randomised, crossover study in healthy adult subjects to determine the relative bioavailability of bedaquiline (fumarate) (TMC207) as tablet (for adults) to an age appropriate formulation and to investigate the food effect of the selected paediatric formulation **Study 4** Open-label, multicenter, single arm study to evaluate the pharmacokinetics, safety, tolerability and anti-mycobacterial activity of TMC207 in combination with a background regimen (BR) of multi-drug resistant tuberculosis (MDR-TB) medications for the treatment of children and adolescents from birth to less than 18 years of

		age who have been diagnosed with confirmed or probable MDR-TB (TMC207-C211)
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s)

1. Treatment of multi-drug resistant tuberculosis

Authorised indication(s):

- SIRTURO is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. See sections 4.2, 4.4 and 5.1. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Authorised pharmaceutical form(s)

Tablet

Authorised route(s) of administration

Oral use